|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
$21,000
|
N/A
|
National Institutes of Health
|
|
ATBC Study
|
ZIA CP010195-03031
|
$1,161,432
|
$92,915
|
N/A
|
DCEG (NCI)
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
$16,800
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
$8,400
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
$16,611
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
$27,936
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
$530,981
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance
|
5R01CA201247-03
|
$511,614
|
|
ABDEL-WAHAB, OMAR
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Master Regulatory MicroRNAs in Glioblastoma
|
5U01CA220841-02
|
$452,813
|
|
ABOUNADER, ROGER
|
UNIVERSITY OF VIRGINIA
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Nanoparticle mediated microenvironmental targeting of CCL3 signaling for the treatment of acute myelogenous leukemia
|
1F31CA228391-01
|
$42,418
|
|
ACKUN-FARMMER, MARIAN
|
UNIVERSITY OF ROCHESTER
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
$111,482
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-04
|
$22,547,116
|
$1,803,769
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
AFRICAN FEMALE BREAST CANCER EPIDERMIOLOGY (AFBRECANE) STUDY
|
5U01HG009784-02
|
$85,000
|
|
ADEBAMOWO, CLEMENT
|
INSTITUTE OF HUMAN VIROLOGY
|
|
Genetic identification of novel mTORC1 regulators and homeostatic signaling mechanisms
|
1F31CA228241-01
|
$44,524
|
|
ADELMANN, CHARLES
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Probing the role of the IRE1alpha-XBP1 pathway in normal and malignant hematopoiesis
|
5K22CA218467-02
|
$192,575
|
|
ADORO, STANLEY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Developing targeted activatable peptides to amplify radiosensitizer delivery
|
5R03CA219744-02
|
$77,500
|
|
ADVANI, SUNIL
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
5R03CA219336-02
|
$74,250
|
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
New Roles for the WTX Tumor Suppressor and Endocytosis in WNT signaling
|
1F31CA228289-01
|
$34,190
|
|
AGAJANIAN, MEGAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-05
|
$382,616
|
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-03S1
|
$154,939
|
$6,198
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-04
|
$737,200
|
$29,488
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
5K08CA218420-02
|
$177,120
|
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Dr. Keiko Akagi, A Bioinformatics Specialist in Cancer Genomics Research at OSU Comprehensive Cancer Center
|
5R50CA211533-03
|
$122,475
|
|
AKAGI, KEIKO
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform
|
5U24CA210950-03
|
$279,908
|
|
AKBANI, REHAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
MULTIMODAL PRECLINICAL CANCER IMAGING AND THERAPY RESEARCH SPECIALIST
|
5R50CA211481-04
|
$170,003
|
|
AKERS, WALTER
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade
|
1R43CA228721-01
|
$299,607
|
|
AKPORIAYE, EMMANUEL
|
VEANA THERAPEUTICS, LLC
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-04
|
$1,367,856
|
$68,393
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
A collaborative structural hub to promote Cancer Center science and drug design
|
5R50CA211440-03
|
$145,562
|
|
ALESHIN, ALEXANDER
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
Modulation of wild type and mutant p53 by HMGA1
|
1F32CA221010-01A1
|
$58,654
|
|
ALEXANDER, KATHERINE
|
UNIVERSITY OF PENNSYLVANIA
|
|
Chemically produced neural progenitors as a delivery vehicle for anti-glioma therapy
|
1R43CA221490-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma
|
5U01CA194389-03
|
$643,804
|
$643,804
|
ALIZADEH, ARASH
|
STANFORD UNIVERSITY
|
|
Tumor Embolization Using A Novel Catheter With Integrated Flow Regulation
|
2R44CA192428-02A1
|
$893,847
|
|
ALLEN, MICHAEL
|
EMBOLX, INC.
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-04
|
$378,171
|
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Cancer Related Health Disparities Training Program
|
5T32CA163184-08
|
$266,221
|
|
ALLEN, MICHELE
|
UNIVERSITY OF MINNESOTA
|
|
Therapeutic resistance in leukemic cells: targeting BCL-2 family and autophagy
|
5R01CA184137-04
|
$362,569
|
|
ALMASAN, ALEXANDRU
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
5U01CA202144-04
|
$741,952
|
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
$2,850
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-48
|
$2,645,581
|
$52,912
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Tumor Plasticity
|
5R35CA220446-02
|
$1,140,000
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy
|
5R01CA198015-04
|
$366,000
|
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$755,842
|
$37,792
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
In vivo regulators of TERT promoter mutant glioblastoma
|
1F32CA228365-01
|
$58,654
|
|
AMEN, ALEXANDRA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
Coordinating Center: Molecular and Cellular Findings of Screen-Detected Lesions
|
5U01CA196386-05
|
$895,779
|
|
AMOS, CHRISTOPHER
|
BAYLOR COLLEGE OF MEDICINE
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-05
|
$307,736
|
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-05
|
$701,988
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The regulation of dendritic cell function by LMYC at steady state and during immune responses to cancer
|
1F31CA228240-01
|
$30,442
|
$7,611
|
ANDERSON, DAVID
|
WASHINGTON UNIVERSITY
|
|
Performance, safety, and efficacy of a new cyrotherapy device for cervical dyspla
|
5UH3CA189923-05
|
$762,683
|
|
ANDERSON, JEAN
|
JOHNS HOPKINS UNIVERSITY
|
Total relevant funding to Non Hodgkins Lymphoma for this search: $138,151,260
|